Lorbrexen 100 mg (Lorlatinib) Tablets
Manufacturer: Everest Pharmaceuticals Ltd.
Distributed by: NP Molecule
Strength: 100 mg
Formulation: Film-coated tablet
Packaging: Bottle of 30 Tablets
Website: www.npmoleculeoncology.com
Contact: npmolecule23@gmail.com | +8801844288466
π¬ Product Description
Lorbrexen 100 mg contains Lorlatinib, a third-generation ALK (anaplastic lymphoma kinase) and ROS1 tyrosine kinase inhibitor, used in the treatment of non-small cell lung cancer (NSCLC) that is positive for ALK or ROS1 gene rearrangements.
Lorlatinib is specifically designed to overcome resistance mutations developed during earlier generations of ALK inhibitors and has excellent penetration of the blood-brain barrier, making it effective for treating brain metastases.
π§ͺ Mechanism of Action
Lorlatinib selectively inhibits:
It blocks signaling pathways that drive cancer cell growth in ALK-positive and ROS1-positive NSCLC, including in tumors with resistance mutations (e.g., ALK G1202R).
π Indications
Lorbrexen 100 mg is indicated for the treatment of:
-
ALK-positive metastatic NSCLC, especially after progression on crizotinib and at least one other ALK inhibitor
-
ROS1-positive metastatic NSCLC (in certain off-label cases, under physician discretion)
π Dosage & Administration
-
Recommended Dose: 100 mg orally once daily
-
Take at the same time each day, with or without food
-
Tablets should be swallowed whole; do not crush or chew
-
Dose modifications may be necessary based on adverse reactions
β οΈ Warnings & Precautions
-
CNS Effects: Cognitive, mood, and speech changes possible
-
Hyperlipidemia: Elevated cholesterol and triglyceride levels are common
-
Liver Toxicity: Monitor liver enzymes regularly
-
Cardiac Effects: May cause QT prolongation
-
Interstitial Lung Disease (ILD): Discontinue if suspected
-
Teratogenicity: Avoid use during pregnancy; use effective contraception
π§Ύ Common Adverse Effects
π¦ Storage & Handling
π Product Categories
-
Pharmaceutical Category: Antineoplastic Agent
-
Drug Class: ALK Inhibitor, ROS1 Inhibitor, Tyrosine Kinase Inhibitor
-
Therapeutic Area: Oncology, Targeted Therapy
-
Indication Area: Non-Small Cell Lung Cancer (NSCLC)
π² Contact & Verification
NP Molecule
π Sector-14, Uttara, Dhaka-1230
π§ npmolecule23@gmail.com
π www.npmoleculeoncology.com
π +8801844288466
πΈ Scan the QR code on the packaging to verify authenticity and access more product details.